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ABSTRACT
In the past few years, a better understanding of the genomic alterations in lung cancer has facilitated a targeted therapy. Lung
adenocarcinomas with epidermal growth factor receptor mutations have a good response to tyrosine kinase inhibitors (TKIs).
Osimertinib is a third-generation TKI approved by the Food and Drug Administration (FDA). Drug-induced liver injury is a wellknown adverse effect of TKIs as a group and reported to show an autoimmune hepatitis-like picture. However, little is known about
the histopathologic changes with osimertinib. We present a case of drug-induced liver injury secondary to osimertinib and discuss
the histopathologic ﬁndings.

INTRODUCTION
Recent developments in the understanding of the molecular biology of lung cancer have led to the use of targeted therapy for speciﬁc
molecular signatures. The most common molecular alterations in lung adenocarcinomas include Ki-Ras2 Kirsten Rat Sarcoma
(KRAS) gene (30%), epidermal growth factor receptor (EGFR; 10%–15%), and BRAF (7%) mutations.1,2 Cases with EGFR mutations
are known to have a high response rate to tyrosine kinase inhibitors (TKIs),3–6 and in particular, EGFR exon 19 deletions are
associated with better outcomes.7 Osimertinib is a third-generation TKI selective for both EGFR TKI–sensitizing mutations and
EGFR Thr790Met resistance mutations.4,5,8 The most common documented adverse events with osimertinib use are diarrhea, skin
toxicity, nausea, and anorexia.5 In the AURA2 (ClinicalTrials.gov identiﬁer: NCT02094261) study, 1 patient developed druginduced liver injury (DILI) manifested by an increase in serum aminotransferase levels (,1%).4 DILI secondary to TKIs such as
imatinib and sorafenib has been associated with hepatocellular necrosis with some reports of concomitant cholestatic injury,
especially with imatinib treatment.9 However, little is known about the histologic features of osimertinib-induced liver injury.

CASE REPORT
A nonsmoker 57-year-old woman with a right lower lobe lung adenocarcinoma presented with disseminated disease to the lymph
nodes, bones, and brain. The patient’s non–small-cell carcinoma had an exon 19 deletion in EGFR (E746-A750del), with low
programmed death-ligand 1 (PD-L1) expression, and was negative for anaplastic lymphoma kinase gene rearrangement. The patient
received palliative whole-brain radiation therapy and was started on osimertinib 40 mg daily. The patient was not taking any other
drugs concomitantly. Subsequently, the patient developed transaminitis of unclear etiology. The patient also complained of chronic
right upper quadrant pain, which was determined to be secondary to cholelithiasis. The patient underwent a cholecystectomy. It
revealed cholesterolosis and multiple stones in the gallbladder but none in the common bile duct. The enzymes continued to increase
even after cholecystectomy, and a liver biopsy was performed 49 days after initiation of treatment with osimertinib, with the aspartate
aminotransferase and alanine aminotransferase (ALT) levels of 519 U/L and 694 U/L, respectively, an alkaline phosphatase level of
86 U/L, and a bilirubin level of 0.6 mg/dL. An abdominal ultrasound before the biopsy showed a normal-sized liver with a normal
echotexture and echogenicity. An abdominal magnetic resonance imaging was also performed and showed a normal liver appearance without steatosis or surface nodularity. The patient had negative serologies for hepatitis A antibody, hepatitis B core
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Figure 1. (A and B) Disrupted lobular architecture secondary to pericentral confluent necrosis and parenchymal collapse, (C) highlighted with
reticulin stain. The asterisk (*) highlights the central vein.

antibody and surface antigen, and hepatitis C antibody. She also
had negative antinuclear antibody and antimitochondrial antibody in serum.
A core needle biopsy from the liver showed a mildly disrupted
lobular architecture on routine hematoxylin and eosin staining,
secondary to pericentral conﬂuent necrosis and parenchymal
collapse, also conﬁrmed by a reticulin stain (Figure 1). There were
no other features to suggest sinusoidal obstruction syndrome: the
central vein appeared intact, and there was no sinusoidal dilatation
or congestion. A mild mixed chronic inﬂammatory inﬁltrate
surrounding the necrotic areas was identiﬁed, predominantly
composed of macrophages with rare lymphocytes and plasma
cells. The portal tracts showed mild nonspeciﬁc chronic inﬂammation, without interface activity. The trichrome stain
showed no portal expansion, periportal or bridging ﬁbrosis. The
bile ducts were preserved and did not show signs of injury. There
was no ductular proliferation. No granuloma, cholestasis, or signiﬁcant steatosis was identiﬁed. Investigating more into the clinical
condition did not reveal any predisposing factors to account for
venous obstruction or an ischemic or cardiogenic process.
Treatment with osimertinib was discontinued, and the liver
enzymes started downtrending, with the aspartate aminotransferase and ALT levels of 54 and 55 U/L, respectively, an alkaline
phosphatase level of 91 U/L, and a bilirubin level of 0.6 mg/dL, 53
days after discontinuation.

DISCUSSION
DILI is one of the leading causes of liver failure in the United
States,10 but an accurate and early diagnosis is challenging and in
most cases is a diagnosis of exclusion. In 2003, the National Institute of Diabetes and Digestive and Kidney Diseases established
the Drug-Induced Liver Injury Network,10 which is a multicenter
observational study of consecutive cases of DILI enrolled at eight
academic medical centers in the United States.10,11
Clinically, DILI is classiﬁed as hepatocellular, cholestatic, or
mixed, on the basis of its biochemical pattern of injury. Our case
is best classiﬁed as hepatocellular, which is a pattern of injury
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deﬁned by an increase in the ALT level greater than 2–5 times
the upper limit and/or ALT/alkaline phosphatase ratio greater than
5.9 Drug-Induced Liver Injury Network lists eighteen distinct histologic patterns of liver injury: acute hepatitis, chronic hepatitis,
acute cholestasis, chronic cholestasis, cholestatic hepatitis, granulomatous hepatitis, macrovesicular steatosis, microvesicular steatosis, steatohepatitis, zonal necrosis, nonzonal necrosis, vascular
injury, hepatocellular alteration, nodular regenerative hyperplasia,
mixed or unclassiﬁed injury, minimal nonspeciﬁc changes, absolutely normal, and massive necrosis.9–11 This case would qualify as
zonal necrosis. Kleiner et al grouped 83% of their 249 cases into 5
histologic patterns: acute hepatitis, chronic hepatitis, acute cholestasis, chronic cholestasis, and cholestatic hepatitis.11 Little is
known about the histological changes of TKI-induced DILI. Some
case reports of DILI secondary to TKIs, speciﬁcally imatinib and
sorafenib, have been associated with hepatocellular necrosis, with
some reports of concomitant cholestatic injury, especially with
imatinib treatment.9 There has been no documentation of histologic changes with DILI so far, from third-generation TKIs.
Our case presented with DILI secondary to osimertinib, which
is a third-generation TKI used in the treatment of EGFR
TKI–sensitizing mutations and EGFR Thr790Met resistance
mutations.4,5,8 In the AURA2 study, only 1 patient (,1%) developed DILI secondary to osimertinib.4 The liver biopsy in our
case showed pericentral conﬂuent necrosis and parenchymal
collapse, as described earlier. Pericentral necrosis has been
reported in other TKIs, but to our knowledge, conﬂuent necrosis has not been previously described secondary to TKIs.
Imaging studies before the biopsy showed a normal liver architecture, highlighting the importance of a liver biopsy in this
setting. The differential diagnosis of pericentral conﬂuent necrosis usually includes acetaminophen toxicity, acute viral
hepatitis, and acute autoimmune hepatitis.9,12 Our patient did
not have histologic or serologic evidence of autoimmune and
acute viral hepatitis and was not taking acetaminophen or any
other drugs concomitantly. Moreover, unlike in acute viral or
autoimmune hepatitis, there was no portal or lobular inﬂammation elsewhere. The patient discontinued treatment
with osimertinib, and the liver enzymes started to decrease and
reached almost normal values 1 month after discontinuation.
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Hirabayashi et al, reported a case of osimertinib-induced fever
and hepatotoxicity after 15 days of treatment.8 Similarly,
Yoshida and Kim13 reported a similar case of grade 2 hepatotoxicity developing 1 month after initiation of osimertinib
treatment.13 No histopathologic ﬁndings were discussed in either of the cases. In both cases, the authors reduced the dose of
treatment without success; however, on oral desensitization, the
patients successfully continue treatment without recurrence
of side effects. More cases are needed to further characterized
DILI secondary to osimertinib and the potential use of oral
desensitization.
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